Retatrutide Black Market Surges Ahead of Lilly's 2027 FDA Filing

A drug that can't be bought legally is selling anyway

Illegal sales of Eli Lilly's experimental obesity drug retatrutide have grown into a large market. The drug has not been approved by any regulator, and it has not yet been submitted to the US Food and Drug Administration. Over the summer of 2026, products sold as retatrutide showed up at strip-mall health spas and on social media marketplaces. Public health experts across the US have raised alarms.11 Doctors are not reacting this way to a supplement or a familiar compound. They are reacting to a molecule still in clinical trials. A clinical professor at the Keck School of Medicine said she had seen this pattern with supplements but never with a drug still under study for FDA approval.14

The market is large and organized. A CBS News investigation found more than 120 websites and more than 50 US clinics selling or promoting retatrutide. Some of the operations are run by licensed physicians and nurse practitioners who argue that the trial data justify skipping the regulatory timeline.17 The New York Times reported that hundreds of thousands of doses may have entered the US in the first four months of 2026. Some went to researchers, but there are concerns that much of the rest reached consumers.14 Lilly says it has reported more than 14,000 websites, ads and social media posts to authorities.12

The main point of this article is that the retatrutide market is not just a repeat of the compounded-GLP-1 boom. It shows that the gap between strong trial results and formal approval can now be filled by an unregulated global supply chain before regulators have even seen an application.

Why demand ran ahead of the evidence

The demand comes from the trial results. Retatrutide acts on three hormone receptors: GLP-1, GIP and glucagon. It is meant to curb appetite, help regulate insulin and increase calorie burn.11 In the pivotal TRIUMPH-1 trial, patients on the 12 mg dose lost an average of 28.3% of their body weight, about 70 pounds, over 80 weeks. About 45% lost 30% or more, compared with 2.2% weight loss on placebo.1 Lilly describes 30% weight loss as a level long associated with bariatric surgery.8 For comparison, approved semaglutide produced roughly 15–17% weight loss in its pivotal trials and tirzepatide about 20–21%.4

Later trials gave more modest but still large results. Adults with type 2 diabetes lost up to 20.8% of body weight in TRIUMPH-2. Patients with severe obesity and cardiovascular disease lost up to 22.6% in TRIUMPH-3.3 TRIUMPH-1 and TRIUMPH-2 were published in full in the New England Journal of Medicine and The Lancet in late September 2026.3

Price also matters. People buying the illegal product reportedly pay around $200 a month. One industry analyst estimates the approved version could have a list price of $1,000 to $1,500 a month.19 When a black-market product costs a fraction of the expected legal price and is promoted with headline trial numbers, demand is predictable.

The buyers are also a specific group. UK research cited in coverage found that men aged 25 to 34 are the most likely to buy the drug illegally, possibly because of its popularity with gym-goers. One researcher who studies performance-enhancing drugs said retatrutide is following the same path as steroids.14

The FDA approval timeline, and where reports diverge

Coverage of when retatrutide might be approved is inconsistent, and some of it is wrong. Lilly announced in July 2026, and repeated in September, that it plans to submit an application in the first quarter of 2027.3 The company had earlier said a filing might come by the end of 2026. The delay was blamed on manufacturing and quality-control (CMC) work, not on clinical data.6 Medscape and PharmaVoice both report the Q1 2027 target.1319 One pharmacy trade report still cited a late-2026 submission and a launch unlikely before early 2028.17 One UK tabloid said approval was expected later this year or early next year, which the filing schedule does not support.14

The more reliable estimate comes from typical review times. FDA review usually takes 10 to 12 months after submission, so approval, if it comes, would likely arrive in late 2027 or 2028.5 There is also a regulatory complication. BioSpace reported that the FDA has treated retatrutide as not qualifying as a biologic, while Lilly intends to file a Biologics License Application. That disagreement is a real regulatory risk.6

That leaves a gap of at least a year, and probably closer to two, between strong public results and legal access. The black market is operating inside that gap.

What the harms look like

Reports of harm are growing. Human exposures to retatrutide reported to US poison centers rose 265% in the first four months of 2026 compared with the end of 2025.1718 The FDA has received about 40 reports of suspected adverse reactions, including heart problems, appendicitis and blurred vision. Fourteen patients were hospitalized, and four cases were classified as life-threatening.14

Australia has seen the most serious cases. Victorian health authorities issued an urgent warning after six people were hospitalized with acute liver damage linked to unapproved retatrutide bought online, through friends or on social media.14 One woman said she bought a vial at a beauty appointment, sourced from a Chinese manufacturer and paid for in cash. Doctors considered a liver transplant before her condition stabilized.14 Investigators suspect a contaminated batch but cannot yet confirm it, partly because so little is known about the drug outside trials.11

The most useful new evidence is a real-world study reported by Medscape. It found that gray-market use was associated with less than half the weight loss seen in trials. It also found that users still had retatrutide's typical rise in heart rate and a higher burden of cardiovascular symptoms.13 The likely explanation is that buyers get the drug's side effects without its full benefit, possibly because of underdosing, degradation or mislabeled products. A Reddit-based study of more than 13,000 self-reported users likewise found fatigue, cravings and elevated heart rate, which led experts to question whether some people are taking fakes.14 Dosing mistakes add to the risk. One UK user told the BBC he accidentally injected eight times the intended dose after mixing a powder with bacteriostatic water.12

The cancer and long-term safety question

The least discussed issue is long-term safety. Like the drugs before it, retatrutide carries class-level concerns. Pharmacist guidance lists thyroid C-cell tumors, pancreatitis and psychiatric events such as depression and suicidal ideation as risks that need the structured monitoring an approved framework provides.17 Controlled trials and post-approval surveillance exist to catch slow-developing signals like cancer risk. A drug with no national drug code, no pharmacy claim and no prescription record is effectively invisible to those systems.13

The products are also often mixed with other things. Clinical notes record gray-market retatrutide combined with other unapproved peptides, including IGF-1 analogues and BPC-157, none of which has been tested in a clinical trial.13 There is a further problem for future research. Patients entering incretin trials may have prior gray-market exposure that standard screening won't detect, which could affect the data that regulators later rely on.13

Enforcement is losing ground

The legal position is clear: the FDA has said consumer sales are illegal, that retatrutide cannot be lawfully compounded, and that "research use only" products may be harmful.15 Enforcement has not kept up. Public Citizen found that of 14 FDA warning letters sent to retatrutide sellers since 2024, 11 recipients were still advertising unapproved peptides as of May, and eight were still selling retatrutide.16 Federal prosecutors in Utah indicted a physician in April, alleging he sold China-sourced peptides, including retatrutide, to more than 200 patients.16 In the UK, regulators seized more than 2,000 unlicensed retatrutide pens at an illegal factory in Northampton.12

Lilly has filed six lawsuits against med spas, a pharmacy and other vendors.11 In August it called on platforms, payment processors and regulators to shut down the trade.15 It has also opened an expanded-access program for some qualifying patients who cannot join a trial.3 The company wants to protect patients, but it also wants to protect a product likely to be very valuable, and its messaging reflects both goals. The expanded-access program can be read as an admission that legal channels were not meeting demand.

The bottom line

Sources broadly agree on the core facts: retatrutide works well in trials, it is not approved, and the black-market version is risky. They differ mainly on timelines, and the most careful reporting points to a Q1 2027 filing with approval no earlier than late 2027. A weekly letter-by-letter enforcement approach cannot keep up with a global peptide supply chain that responds quickly to trial results and social media.16 Until legal supply exists at an affordable price, physicians' main tools are to ask patients directly about peptide use, monitor heart rate, and set realistic expectations.13